CLINICAL_TRIALS
trial_result
· 2024-12-20
Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia [Phase 3]
Summary
A Phase 3 study evaluating TNX-102 SL taken daily for fibromyalgia has completed. The trial results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2024-12-20